2024-07-24 03:06:53 ET
Summary
- Rigel Pharmaceuticals focuses on innovative therapeutics for hematological conditions and cancers, with FDA-approved products Tavalisse, Rezlidhia, and Gavreto targeting specific diseases.
- RIGL’s pipeline also includes promising drug candidates like R289, targeting lower-risk myelodysplastic syndromes and other kinase-related diseases.
- Gavreto, recently acquired by RIGL, targets RET fusion-positive NSCLC and thyroid cancer, with significant potential for revenue growth.
- I believe the stock is undervalued relative to peers, with a potential pathway to becoming cash flow positive by 2025, making it a strong buy.
- However, there are competition and commercialization risks. Despite this, RIGL's diversified product portfolio and promising pipeline support a positive long-term outlook.
Read the full article on Seeking Alpha
For further details see:
Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential